Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Lenalidomide in MDS and AML-TLD
NCT00867308Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2009
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jul 2009; status: terminated.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00867308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00867308.